The gut microbiome is intimately involved in the regulation of MS pathophysiology, including via its inhibition of aSMase/ceramides, platelet activation, and the optimization of orexin and melatonin’s circadian modulation of mitochondrial function. This evidence concerns the gene HCRT and myeloid sarcoma.